Navigation Links
Drug inhibits neuroblastoma blood supply in pre-clinical tests
Date:4/24/2009

SAN DIEGO - Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have found a way to prevent blood vessels from aiding the growth of neuroblastoma, a childhood cancer. The pre-clinical study was presented today in a platform session at the 22nd annual meeting of the American Society of Pediatric Hematology/Oncology.

Investigators at the Children's Cancer Hospital at M. D. Anderson have discovered that the drug, AMD3100, hinders the formation of tumor blood vessels and reduces human neuroblastoma tumor growth by more than 75 percent in mice.

The drug blocks interaction between SDF-1a and its receptor CXCR4. This pathway plays an important role in signaling cells to different areas of the body. More specifically, the study suggests that SDF-1a plays a role in differentiating and/or attracting pericyte-like cells to neuroblastoma tumors.

Pericytes are essential for organizing blood vessels to feed tumors. Without pericytes, blood vessels are dysfunctional and tumors are left without a vital blood source. This study found that AMD3100 decreased the number of pericyte-like cells in neuroblastoma tumors by close to 90 percent.

"AMD3100 works by shutting down the process that tumors need to set up vascular systems," says Patrick Zweidler-McKay, M.D., Ph.D., assistant professor at the Children's Cancer Hospital and senior investigator on the study. "The drug doesn't kill neuroblastoma cells directly, but it prevents tumors from growing rapidly by disrupting their blood supply."

In tissue culture, investigators were also able to show how AMD3100 prevented neuroblastoma cells from migrating toward SDF-1a ligands. SDF-1a is present at high levels in the bone marrow, one of two areas where neuroblastoma most commonly metastasizes.

"There is the possibility that this therapy could help prevent neuroblastoma metastasis to the bone marrow. However, more studies are needed to investigate this theory," says Zweidler-McKay.

According to the American Cancer Society, approximately 650 children, mainly under the age of five, are diagnosed with neuroblastoma in the United States each year. Close to two-thirds of these children are diagnosed after the cancer has metastasized to other parts of the body. For these patients with high-risk neuroblastoma, long-term survival is less than 40 percent because the tumors are often resistant to traditional chemotherapy.


'/>"/>

Contact: Lindsay Anderson
lindsay.anderson@gabbe.com
212-220-4444
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Helicobacter pylori inhibits intercellular communication of cultured gastric cells
2. Blocking protein kills prostate cancer cells, inhibits tumor growth, Jefferson scientists find
3. Embryonic Stem Cell Protein Inhibits Melanoma
4. Penn scientists find a protein that inhibits Ebola from reaching out to infect neighboring cells
5. Ingredient found in green tea significantly inhibits breast cancer growth in female mice
6. Calorie restriction limits Calorie restriction inhibits, obesity fuels development of epithelial can
7. Calorie restriction inhibits, obesity fuels development of epithelial cancers
8. Grapefruit Compound Inhibits Hepatitis C Virus
9. Herpes drug inhibits HIV replication, but with a price
10. Oncogene inhibits tumor suppressor to promote cancer: Study links B-RAF and LKB1
11. Drug Inhibits Colon Cancer in Mice
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug inhibits neuroblastoma blood supply in pre-clinical tests
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines ... despite scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument that ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... clinic serving San Francisco and environs, is proud to announce an upgrade to ... information on the upgraded Yelp page on topics as diverse as Platelet Rich ...
(Date:2/26/2017)... ... 2017 , ... This is an extension of airmid’s scope ... ISO/IEC 17025:2005 INAB accredited for Der p 1 (house dust mite allergen) & ... standard that sets out requirements for the technical competence of testing and calibration ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... technology standard in staffing, scheduling, and reporting for healthcare organizations. This comprehensive ... throughout the entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource ...
(Date:2/25/2017)... ... , ... FCPX users now have the ability to sharpen a desired color ... users have total control over sharpening amount, sharpening radius, threshold, horizontal sharpening, vertical sharpening, ... users can visually see the color range effected with ease all within Final ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017 Report analyzes the worldwide markets for ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ... for the period 2015 through 2022. Also, a six-year historic ... are derived from primary and secondary research. Company profiles are ...
(Date:2/24/2017)... ITL Limited, ( ASX : ITD ), une société de ... excellents résultats semestriels clos le 31 décembre 2016 par ... « Résultats et mise à jour sur la croissance biomédicale ... Faits marquants Bénéfice ... hausse de 104 %) Bénéfice par action ...
(Date:2/24/2017)... -- This report analyzes the worldwide markets for Chiral Technology ... Products: Intermediates, Analytical, and Others. The End Use markets ... The report provides separate comprehensive analytics for the US, ... , and Rest of World. Annual estimates and forecasts ... a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology: